Satori Pharmaceuticals

Description

• Satori Pharmaceuticals is committed to the development of disease modifying therapies for Alzheimers disease through innovative approaches that selectively target the key neurotoxic mediators and pathways of this debilitating neurodegenerative disorder. Satori (www.satoripharma.com) was founded in 2005 by Dr. Mark Findeis and PureTech Ventures and is guided by a world renowned group of advisors including Dennis Selkoe, M.D., the Vincent and Stella Coates Professor of Neurologic Diseases at the Brigham and Women's Hospital, an affiliate of Harvard Medical School; DonaldPrice, M.D.,Professor of Pathology, Neurology, and Neuroscience and Vice Chair for Research in the Department of Pathology and Director of the Division of Neuropathology at The Johns Hopkins University School of Medicine; Christopher Eckman, Ph.D., Director for Research and Academic Affairs, MidAtlantic Neonatology and Atlantic Neonatal Research Institute Atlantic Health Systems and Professor of NeuroScience at the Mayo Clinic; David Holtzman, M.D., Andrew B. and Gretchen P. Jones Professor of Neurology and Molecular Biology & Pharmacology at the Washington University School of Medicine in St. Louis; and Paul J. Reider, Ph.D., a faculty member in the department of chemistry at Princeton University and a former senior leader of R&D at Amgen and Merck. Satori successfully closed a $22M Series B round of financing in early 2009 with a leading investment syndicate of InterWest Partners, New Enterprise Associates and Prospect Venture Partners.
• 

  Headquarters:281 Albany St , Cambridge, Massachusetts, United States

  More
• 

  Phone Number: +1 617-547-0022

• 

  Website: https://www.satoripharma.com

• 

  Employees:2

• 

  Revenue:$1 - 10M

• 

  Legal Name:Satori Pharmaceuticals

• Satori Pharmaceuticals's Social Media

  
• Is this data correct?

• |  NAICS Code: 446110  |

  Show More